MEDIA ADVISORY --- BIO 2001: Highlight of Events for Wednesday, June 27
| 7 - 8:00 a.m. Plenary Breakfast Ballroom 6 |
2001 Biotechnology Heritage
Award, presented to Dr. Francis S. Collins, Director of the Human Genome
Institute at NIH and Dr. J. Craig Venter, Celera Genomics Corporation. (Note:
Collins and Venter will be available to the media immediately following
the breakfast in room 5B.)
|
| 8:15 - 9:45 a.m. Food and Ag Track Session Upper Level, Room 2 |
The Global Trade Dilemma,
led by Paul Drazek, President, DTB Associates, panel speakers will discuss
how increasingly expensive regulations impede international trade, largely
between developing countries. Speakers will review the current impacts of
trade, including costs and barriers. (Note: Panelists will be available
to the media immediately following the track session in room 5B.)
|
| 8:15 - 9:45 a.m. CommunicationsMezzanine Level, Room 16B |
Biotech in the Media -
How Are We Doing?, chaired by Dan Eramian, Vice President, Communications,
Biotechnology Industry Organization, a panel of reporters who cover the
biotechnology industry will discuss the effectiveness of the industry in
presenting itself and its case to the public with regards to the announcement
of the Human Genome Project, the introduction of GMO crops and foods and
the prescription drug debate, among other issues.
|
| 10:15 - 11:45 a.m. Food and Ag Track Session Upper Level, Room 2 |
Lack of Global Harmonization
and Challenges for Developing Countries, chaired by L. Val Giddings,
Vice President, Food and Agriculture, Biotechnology Industry Organization,
academics from the U.S. and Africa address the impact of agricultural biotechnology
for developing countries.
|
| 11 a.m. Press Conference Upper Level, Room 5B |
Israeli Export Institute:
The Israeli Chief Scientist of the Israeli Ministry of Trade and Compugen
Ltd., will give an overview of the biotechnology industry in Israel.
|
| 12 - 1:45 p.m. Plenary LuncheonBallroom 6 |
Naomi Judd, Grammy award-winning
singer, and Alan Hobson, cancer survivor and Mt. Everest climber (Note:
Judd and Hobson will be available to the media immediately following in
room 5B.)
|
| 2- 3:30 p.m. Industrial and Environmental Track Session Upper Level, Room 3 |
Global Climate Change and
Energy - Can Modern Biotechnology Provide Workable Solutions?, led by
James S. McLaren, Ph.D., President, Inverizon International Inc., speakers
will discuss the broad-ranging positive impacts that industrial biotechnology
solutions can have on issues pertaining to our environment.
|
| 2- 3:30 p.m. Policy/Ethics Track Session UMezzanine Level, 16A |
Conserving Endangered Species
in the Genomics Era, this session brings scientists working at the interface
of genomics and conservation from the world-famous San Diego Zoo, the biotechnology
industry and the Human Genome Project to present new research findings and
initiatives for benefiting endangered species. Chaired by Oliver A. Ryder,
Ph.D., Kleberg Genetics Chair, Center for Reproduction of Endangered Species.
|
| 2 - 3:30 p.m. Science Track Session Upper Level, Room 9 |
Hitting the Target - Accurate
Drug Delivery, the panel of speakers, led by Paul Drayson, Ph.D., CEO.
PowerJect Pharmaceuticals plc, has been chosen to provide a broad overview
of the current state of the art in biotech drug delivery and will provide
thoughtful, provocative insights into the challenges and opportunities ahead
for the industry.
|
| 2 - 3:30 p.m. Science Track Session Upper Level, Room 10 |
Regenerative Medicine: Sustaining
Human Health by Harnessing the Body's Regenerative Capabilities, Co-chairs
Doros Platika, M.D., President and CEO, Curtis, Inc. and Daniel Hartmann,
Faculty of Pharmacy, will discuss how regenerative medicine seeks to harness
the body's inherent ability to repair damage caused by disease, trauma or
age.
|
| 3:30 p.m. Press Conference Upper Level, Room 5B |
Biotechnology Industry Organization and Ardana Bioscience to Donate $30,000 Grant to World-Famous San Diego Zoo, presented to Dr. Oliver A. Ryder, Kleberg Genetics Chair, Center for Reproduction of Endangered Species, by Simon G. Best, Chief Executive Officer, Ardana Bioscience, Board of Directors, Biotechnology Industry Organization; David Robinson, Chairman, Biotechnology Industry Organization, Chairman, President and Chief Executive Officer, Ligand Pharmaceuticals, Inc.; Joe Panetta, President and Chief Executive Officer, BIOCOM/san diego and Ray Briscuso, Executive Director, Biotechnology Industry Organization.
|
|
4 - 5:30 p.m. |
Global Balancing Act: Intellectual
Property Rights and the Plight of the Poor, Anne G. K. Solomon, Senior
Adviser and Former Deputy Assistant Secretary of State for Science, Technology
and Health, will lead a discussion about intellectual property rights (IPR)
protection and its importance to the vitality of technological innovation
and commercialization.
|
|
4 - 5:30 p.m. |
Cloning and Stem Cells:
New Controversies, led by Michael J. Werner, Esq., Director, Federal
Government Relations/Bioethics Counsel, Biotechnology Industry Organization,
this session will examine the NIH policy to allow federal funding for research
using stem cells, which is currently under review by the Bush administration.
|
|
4 - 5:30 p.m. |
Innovative Research and Infectious
Diseases, a panel led by Gerald Yakatan, Ph.D., President and CEO, Avanir
Pharmaceuticals, will discuss some of the cutting-edge research that could
lead to treatments for infectious diseases such as hepatitis, herpes, malaria,
HIV and the common cold.
|
|
2 - 3:30 p.m. |
The Future of DNA Microarrays
and Bioinformatics in Research and Diagnostics, chaired by August Sick,
Senior Manager, Business Development, Invitrogen Corporation, this session
will present recent applications demonstrating the power of microarrays
and advanced bioinformatics technologies in identifying differentially expressed
biomarker genes.
|
|
2 - 3:30 p.m. |
Oversight of Gene Therapy:
Protecting Patients and Promoting Research The FDA and NIH have recently formally issued plans that would dramatically change the regulatory environment for companies doing gene therapy experiments. This program, chaired by Michael J. Werner, Esq., Director, Federal Government Relations/Bioethics Counsel, Biotechnology Industry Organization, will discuss several important issues surrounding regulation in the industry.
|
|
2 - 5:30 p.m. |
Mergers & Acquisitions
Symposium, chaired by Richard A. Leavitt, Principal, William Gallagher
Associates Insurance Brokers, Inc., and Stephen Ferruolo, Shareholder, Heller
Ehrman White & McAuliffe LLP, speakers on this panel will address the
future of genomics and the information challenge it poses.
|
|
3 p.m. |
Florence Wambugu, Ph.D.,
Director, ISSA AfriCenter, Kenya, will discuss her book, "Modifying
Africa: How Biotechnology Can Benfit the Poor and Hungry: A Case Study from
Kenya."
|
|
4 p.m. |
MediChem/Neurocrine Announcement,
MediChem (NASDAQ:MCLS) a Chicago-based drug discovery technology and services
company, and Neurocrine Biosciences (NASDAQ: NBIX), a San Diego-based biopharmaceutical
discovery and development company, will announce that they have entered
into a two-year collaborative GPCR agreement in proteomics for new drug
development.
|
|
4 - 5:30 p.m. |
Animal, Mineral or Vegetable:
Which Model for Product Discovery, John A. Ryals, Ph.D., President and
CEO, Paradigm Genetics, chairs a discussion about the utility of different
gene-based discovery models that have influenced the success of the genomics
industry.
|
|
4 - 5:30 p.m. |
The Impact of State Drug
Price Control Schemes on Emerging Biotech Companies, Thomas C. Norton,
Senior Vice President, SPECTRUM Science Public Relations, chairs a discussion
of the consequences of state drug price control programs.
|
|
4 - 5:30 p.m. |
Managing Diabetes: Advances
in Insulin Therapy from Novel Delivery Systems, Lars Karlsen, Senior
Vice President, Head of Project Portfolio Managements, Novo Nordisk A/S,
chairs a discussion of how recent advances in insulin delivery will improve
patient compliance with insulin regimens and quality of life.
|
|
4 - 5:30 p.m. |
Raiders of the Lost Genome:
Gene Analysis on the Post-Genome Era, chaired by Teresa W. Ayers, CEO
and Director, Genomica, this panel will review and discuss a variety of
new technologies that will facilitate the deciphering of genetic data and
provide gene function information for product development.
|
|
4 - 5:30 p.m. |
Innovative Research and
Infectious Diseases, a panel led by Gerald Yakatan, Ph.D., President
and CEO, Avanir Pharmaceuticals, will discuss some of the cutting-edge research
that could lead to treatments for infectious diseases such as hepatitis,
herpes, malaria, HIV and the common cold.
|
|
4 - 5:30 p.m. |
Stopping Global Pandemics
in the Track, chaired by Franklin Berger, Senior Analyst, JP Morgan.
|